- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 277 Park Avenue New York NY United States of America 10172
- IPO Date
- Sep 17, 1993
- Business
- JPMorgan U.S. Equity Fund (JMUEX) is an open-end mutual fund that seeks high total return primarily through a portfolio of U.S. large-cap equity securities; it invests at least 80% of its assets in common stocks of large- and medium-capitalization U.S. companies, with up to 20% permitted in foreign equities including depositary receipts. The fund employs a research-driven, fundamental analysis approach to construct a high-conviction portfolio of attractively valued stocks across sectors, maintaining sector weightings closely aligned with the S&P 500 Index to achieve similar volatility while targeting outperformance; top holdings as of September 30, 2025, include NVIDIA Corp. (9.2%), Microsoft Corp. (8.8%), and Apple Inc. (7.4%), with approximately 51 holdings, a weighted average market cap of $1,437 billion, and a 1-year forward P/E ratio of 26.24. Share classes include L Shares (JMUEX, ticker symbol, launched September 17, 1993, with a $3 million minimum initial investment and net expense ratio of 0.57%), alongside A (JUEAX), C (JUECX), I (JUESX), R2 (JUEZX), R3 (JUEPX), R4 (JUEQX), R5 (JUSRX), and R6 (JUEMX) shares; the fund is part of JPMorgan Mutual Fund Investment Trust, managed by J.P. Morgan Investment Management Inc., with lead portfolio manager Scott Davis (30 years experience) and co-manager Shilpee Raina (20 years experience).
Launched in 1993 as part of a strategy originating from a predecessor fund in 1985, the fund is domiciled in the United States and headquartered at 277 Park Avenue, New York, New York, within the asset management division of JPMorgan Chase & Co. It operates in the large blend category, targeting institutional and retirement investors seeking U.S. equity exposure similar to the S&P 500 benchmark, with total assets under management of approximately $35.55 billion as of September 30, 2025. The fund maintains a beta of 1.00 and a 3-year Sharpe ratio of 1.36 relative to the benchmark, reflecting market-like volatility.
In recent periods through mid-2025, portfolio managers adjusted positions amid market shifts, including selling out of UnitedHealth Group, reducing NXP Semiconductors, underweighting Tesla and Palantir, and flipping Broadcom from underweight to overweight; these changes addressed underperformance in the first 10 months of 2025, where the fund trailed the S&P 500 by over 2 percentage points due to stock-specific factors. The fund received a Morningstar Silver Medalist Rating as of November 27, 2024, and maintains a 4-star overall Morningstar rating (among 1,226 large blend funds) as of September 30, 2025, with 5 stars over 10 years. No major acquisitions, funding rounds, partnerships, or structural reorganizations have been reported for the fund in the last 1-2 years, with focus remaining on active stock selection and sector-neutral positioning.